-+ 0.00%
-+ 0.00%
-+ 0.00%

Century Therapeutics Q2 FY26 net loss widens to $34.55 million

PUBT·08/12/2026 12:04:50
Listen to the news
Century Therapeutics Q2 FY26 net loss widens to $34.55 million
  • Century Therapeutics posted a GAAP net loss of USD 34.6 million, widening from USD 32.5 million a year earlier.
  • R&D expense fell 27.1% to USD 19.6 million, due to lower headcount and facility costs tied to portfolio prioritization.
  • G&A expense dropped 25.6% to USD 5.8 million; cash, cash equivalents, and investments climbed to USD 197.2 million.
  • Runway extended into 1Q 2029; CNTY-813 IND filing remains on track for 4Q 2026 with initial clinical data expected in 2H 2027.
  • Pre-IND FDA meeting aligned on nonclinical package, Phase 1 manufacturing and testing, and Phase 1/2 trial design; CNTY-308 still slated for clinic entry in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120800PRIMZONEFULLFEED9808489) on August 12, 2026, and is solely responsible for the information contained therein.